文献速递神经核医学放射性药物与辐射防护

[18F]LW223(新型TSPO PET示踪剂)首次人体全身生物分布与剂量学分析

First human whole-body biodistribution and dosimetry analysis of [18F]LW223, a novel TSPO PET radiotracer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-01-10

本研究在健康成人志愿者中静脉注射184.3 ± 20.2 MBq [18F]LW223后行250分钟全身PET显像,分析生物分布与剂量学。示踪剂主要经肝胆排泄,关键器官为肠道,有效剂量为11.8 ± 0.9至12.5 ± 0.9 µSv/MBq,符合监管机构辐射限值,适合转化至人体临床研究。

要点

  • [18F]LW223主要经肝胆排泄,关键器官为肠道,未见体内脱氟证据。
  • 有效剂量为11.8 ± 0.9至12.5 ± 0.9 µSv/MBq,符合监管机构推荐限值。
  • 观察者间VOI变异对器官及全身有效剂量估计无影响。

核心结论

  • [18F]LW223主要经肝胆排泄,无体内脱氟证据,符合监管机构辐射限值,适合转化至人体临床研究。

研究设计与样本

  • 健康成人志愿者静脉注射184.3 ± 20.2 MBq [18F]LW223后行250分钟全身PET显像,由三名独立观察者手动勾画VOI并计算驻留时间与剂量。

主要发现

  • 人体生物分布再现已知TSPO表达组织分布,主要消除途径为肝胆排泄,关键器官为肠道。
  • 测量期间经肾脏排泄的累积放射性小于10%,任何受试者均未观察到提示体内脱氟的骨摄取。
  • 有效剂量范围为11.8 ± 0.9至12.5 ± 0.9 µSv/MBq,观察者间VOI变异对器官及全身有效剂量估计无影响。

关键数值与推荐

  • 有效剂量为11.8 ± 0.9至12.5 ± 0.9 µSv/MBq,符合监管机构推荐限值,与[18F]FDG等已报道[18F]标记示踪剂一致。

临床怎么用

  • 支持[18F]LW223作为TSPO PET示踪剂转化至人体临床研究,用于神经炎症、心血管炎症及肿瘤等炎症成像。

局限性

  • 研究纳入健康成人志愿者,未报告患者人群数据;测量期间经肾脏排泄累积放射性小于10%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The 18 kDa translocator protein (TSPO) has been a central molecular target for imaging inflammation in the preclinical and clinical research settings across a plethora of applications, including neuroinflammation, cardiovascular inflammation and cancer. Recently, we reported the development of [18F]LW223 as a third-generation TSPO positron emission tomography (PET) radiotracer with binding to human TSPO independent of the rs6971 genetic polymorphism. This study reports the first whole-body human analysis, including biodistribution and dosimetry calculations, following intravenous administration of [18F]LW223. METHODS: Whole-body PET images were acquired over 250 min after intravenous bolus injection of 184.3 ± 20.2 MBq of [18F]LW223 in healthy adult human volunteers. Volumes of interest (VOIs) in different source organs were manually delineated by three independent observers, then time-activity curves were generated for residency times calculations for subsequent quantification of radiation equivalent and effective doses using OLINDA/EXM 2.2 software. RESULTS: The radiotracer biodistribution in humans recapitulated known TSPO expression in various tissues. The main elimination route was found to be hepatobiliary, and the critical organ was the intestine. The cumulated radioactivity excreted by the kidneys was < 10% over the measurement period and no bone uptake suggestive of in vivo defluorination was observed in any of the study subjects. The effective dose ranged between 11.8 ± 0.9 and 12.5 ± 0.9 µSv/MBq. Inter-observer VOI variability had no impact on estimated organ and whole-body effective doses. CONCLUSION: [18F]LW223 is predominantly excreted by the hepatobiliary route with no evidence of in vivo defluorination but demonstrates marked uptake into tissues with known TSPO expression. It complies with radiation limits and guidelines recommended by regulatory authorities and is in line with previously reported [18F]-labelled radiotracers, such as [18F]fluorodeoxyglucose. [18F]LW223 is suitable for translation into human clinical studies.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Khaing PH, MacAskill MG, Xiao J, et al. First human whole-body biodistribution and dosimetry analysis of [18F]LW223, a novel TSPO PET radiotracer. Eur J Nucl Med Mol Imaging. 2026. PMID: 41518399. doi:10.1007/s00259-025-07722-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。